Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 75Burkitt Lymphoma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Myelodysplastic Syndromes 13Leukemia 10Lymphoma, Mantle-Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Leukemia, Myelomonocytic, Chronic 5Recurrence 4Blast Crisis 4Sarcoma, Myeloid 3Lymphoma 3Leukemia, Monocytic, Acute 3Hematologic Neoplasms 3Down Syndrome 3Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Targeted Therapy 1

Interventions

Cytarabine 3venetoclax 2Cladribine 2quizartinib 1pegylated granulocyte colony-stimulating factor 1Razoxane 1Mitoxantrone 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Cytarabine × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡